ELDN · Eledon Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $17.20M | - | $14.97M | $20.28M | $13.53M | - | $16.52M | $10.11M | $7.41M | - |
| SG&A | $3.98M | - | $4.10M | $4.46M | $4.43M | - | $3.99M | $4.40M | $3.46M | - |
| Total Operating Expenses | $21.18M | - | $19.07M | $24.73M | $17.96M | - | $20.51M | $14.50M | $10.87M | - |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | ($21.18M) | - | ($19.07M) | ($24.73M) | ($17.96M) | - | ($20.51M) | ($14.50M) | ($10.87M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($39.02M) | - | ($17.46M) | ($11.22M) | ($6.50M) | - | $76.97M | ($44.91M) | ($10.29M) | - |
| EPS - Basic | ($0.33) | - | ($0.21) | ($0.13) | ($0.08) | - | $1.05 | ($1.06) | ($0.34) | - |
| EPS - Diluted | ($0.33) | - | ($0.21) | ($0.13) | ($0.08) | - | ($0.32) | ($1.06) | ($0.34) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.15M | $22.81M | $3.67M | $5.74M | $8.50M | $20.55M | $6.75M | $26.04M | $5.66M | $4.61M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $6.58M | $3.63M | $4.63M | $5.83M | $2.90M | $5.83M | $5.86M | $2.15M | $1.86M | $967.0K |
| Current Assets | $113.57M | $135.69M | $96.30M | $111.40M | $127.72M | $143.73M | $81.51M | $87.22M | $47.98M | $56.13M |
| Total Assets | $146.67M | $169.01M | $129.86M | $144.91M | $161.31M | $177.41M | $114.58M | $120.48M | $80.82M | $89.07M |
| Current Liabilities | $13.46M | $18.34M | $14.30M | $13.72M | $9.19M | $11.58M | $12.49M | $6.03M | $4.25M | $3.90M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $46.21M | $32.23M | $38.80M | $38.88M | $46.73M | $59.27M | $38.52M | $128.98M | $6.00M | $5.65M |
| Stockholders' Equity | $44.76M | $81.08M | $35.36M | $50.33M | $114.58M | $118.14M | $76.06M | ($8.50M) | $74.82M | $83.42M |
| Retained Earnings | ($440.23M) | ($401.20M) | ($390.76M) | ($373.30M) | ($362.08M) | ($355.59M) | ($310.97M) | ($387.94M) | ($253.49M) | ($243.19M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($22.61M) | - | - | - | ($16.06M) | - | - | - | ($8.74M) | - |
| Investing Cash Flow | $5.96M | - | - | - | $3.89M | - | - | - | $9.78M | - |
| Financing Cash Flow | - | - | - | - | $115.0K | - | - | - | $1.0K | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -26.6% | - | -13.4% | -7.7% | -4.0% | - | 67.2% | -37.3% | -12.7% | - |
| Return on equity | -87.2% | - | -49.4% | -22.3% | -5.7% | - | 101.2% | 528.3% | -13.8% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 8.44 | 7.40 | 6.74 | 8.12 | 13.91 | 12.42 | 6.53 | 14.48 | 11.30 | 14.41 |
| Quick ratio | 8.44 | 7.40 | 6.74 | 8.12 | 13.91 | 12.42 | 6.53 | 14.48 | 11.30 | 14.41 |
| Cash ratio | 0.46 | 1.24 | 0.26 | 0.42 | 0.92 | 1.77 | 0.54 | 4.32 | 1.33 | 1.18 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 3.28 | 2.08 | 3.67 | 2.88 | 1.41 | 1.50 | 1.51 | -14.17 | 1.08 | 1.07 |
| Liabilities / Assets | 0.32 | 0.19 | 0.30 | 0.27 | 0.29 | 0.33 | 0.34 | 1.07 | 0.07 | 0.06 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 7.7x | - | 5.7x | 4.2x | 2.3x | - | 1.8x | - | 0.8x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -17.9% | - | 7.0% | -70.5% | -65.3% | - | -83.2% | -40.1% | 2.2% | - |
| Net income growth (YoY) | -500.8% | - | - | 75.0% | 36.9% | - | - | -368.8% | 4.4% | - |
| EPS growth (YoY) | -312.5% | - | 34.4% | 87.7% | 76.5% | - | 8.6% | -165.0% | 54.7% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -60.9% | -31.4% | -53.5% | - | 53.1% | 41.6% | -16.7% | - | 0.0% | -0.9% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Eledon Pharmaceuticals against the 5 most active filers in the same SIC group.